Method for producing protein having nampt activity and nmn

By obtaining highly active NAMPT proteins from Bisgaardia hudsonensis and Chitinophaga rupis, combining DNA encoding and recombinant technologies, the existing problems of low productivity and high cost are solved, and efficient and inexpensive NMN manufacturing is achieved.

CN118984876APending Publication Date: 2024-11-19KYOWA HAKKO BIO CO LTD
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202380034876.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-28
Filing Date
2023-03-28
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The existing nicotinamide single nucleotide (NMN) manufacturing methods are low in productivity and cost, and require more efficient and inexpensive manufacturing methods.

Method used

DNA encoding and recombination techniques were performed to improve NMN productivity in E. coli by obtaining proteins with highly active nicotinamide phosphotransferase (NAMPT) from Bisgaardia hudsonensis and Chitinophaga rumpis.

Benefits of technology

The productivity of nicotinamide single nucleotide (NMN) is significantly improved, providing an efficient manufacturing method and reducing production costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
  • Figure SMS_4
    Figure SMS_4
Patent Text Reader

Abstract

A protein according to the present invention is a protein having nicotinamide phosphoribosyltransferase activity and described in any one of [1] to [3] below. [1] A protein comprising an amino acid sequence represented by SEQ ID NO: 3 or 5; [2] a mutant protein comprising an amino acid sequence obtained by deleting, substituting, inserting or adding 1-20 amino acids in the amino acid sequence represented by SEQ ID NO: 3 or 5; [3] A homologous protein comprising an amino acid sequence having 90% or more consistency with the amino acid sequence represented by SEQ ID NO: 3 or 5.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a protein having nicotinamide phosphoribosyltransferase (NAMPT) activity and a method for producing nicotinamide mononucleotide (NMN) using the protein. Background Art

[0002] Nicotinamide mononucleotide (NMN) is a precursor of nicotinamide adenine dinucleotide (NAD) used as an electron transporter in mammals. It is known to have various functions such as activation of mitochondria and sirtuin genes, and is expected to be used as a supplement (Non-Patent Document 1, Non-Patent Document 2).

[0003] As methods for producing NMN, chemical synthesis (Patent Document 1), NAD enzymatic hydrolysis (Non-Patent Document 3), and extraction from yeast (Patent Document 2) are known. However, these methods have the problems of low productivity and high preparation cost, and a cheaper and more efficient production method is needed.

[0004] As a more efficient manufacturing method, it is known that NMN is produced by condensing nicotinamide (NAM) with phosphoribosyl pyrophosphate (PRPP) produced by an enzymatic method or a biological method in the body (non-patent documents 4, 5, 6 and patent document 3). In the condensation reaction of nicotinamide and PRPP, nicotinamide phosphoribosyltransferase (NAMPT) is used. It is known that NAMPT is also involved in NMN synthesis in the human body (non-patent document 7) and is considered to be a key enzyme for NMN synthesis.

[0005] As NAMPT, for example, NAMPT from Haemophilus ducreyi disclosed in Non-Patent Document 4 can be cited. In addition, Non-Patent Document 5 discloses Napmt from Shewanella oneidensis, Sphingopyxis sp. C-1, Chitinophagapinensis, Homo sapiens, Sus scrofa, Mus musculus, Boleophthalmus pectinirostris, Rhinopithecus roxellana, Pteropus alecto, and Xanthomonas translucens, and discloses that among these, when Napmt from Sphingopyxis sp. C-1 or Chitinophagapinensis is used, high NMN productivity is shown.

[0006] Prior art literature

[0007] Patent Literature

[0008] Patent Document 1: International Publication No. 2016 / 160524

[0009] Patent Document 2: International Publication No. 2017 / 022768

[0010] Patent Document 3: International Publication No. 2019 / 065876

[0011] Non-patent literature

[0012] Non-patent literature 1: Kim Baumann, “Counteracting toxic protein aggregation”, Nature Reviews Molecular Cell Biology 17 (2016) 679-690

[0013] Non-patent literature 2: Rui-Xiong Huang et al., "Nicotinamide mononucleotideattenuates glucocorticoid-induced osteogenic inhibition by regulating theSIRT1 / PGC-1α signaling pathway", Molecular Medicine Reports 22 (2020) 145-154

[0014] Non-patent document 3: E. Harth et al., "Control of photosynthetic oxygen evolution by the internal Ph of the chloroplast thylakoid Inhibition of photosynthetic oxygen evolution by uncouplers at high Ph and restoration ofelectron flow by an artificial electron donor for photosystem II", FEBSLetters 42 (1974) 161-164

[0015] Non-patent document 4: GC Marinescu, “β-nicotinamide mononucleotide (NMN) production in Escherichia coli”, Scientific Reports 8(2018) 12278

[0016] Non-patent document 5: Shinichiro Shoji et al., "Metabolic design for selective production of nicotinamide mononucleotide from glucose and nicotinamide", Metabolic Engineering 65 (2021) 167-177

[0017] Non-patent literature 6: Kazane Sugiyama et al., “Nicotinamide mononucleotide production by fructophilic lactic acid bacteria”, Scientific Reports 11(2021) 7662

[0018] Non-patent literature 7: Antje Garten et al. “Nampt: linking NAD biology, metabolism and cancer”, Trends in Endocrinology & Metabolism 20 (2009) 130-138 Summary of the invention

[0019] Problems to be solved by the invention

[0020] As described above, although various methods are known for producing NMN from nicotinamide by expressing NAMPT from a foreign organism in microorganisms such as Escherichia coli, their productivity is not sufficient. In order to produce NMN more efficiently, it is necessary to explore NAMPT that is highly active and can produce NMN efficiently.

[0021] An object of the present invention is to provide a protein having enhanced nicotinamide phosphoribosyltransferase (NAMPT) activity and a method for producing nicotinamide mononucleotide using the protein.

[0022] Methods used to solve problems

[0023] The present inventors conducted intensive studies to provide a novel protein having NAMPT activity and found that NAMPT from Bisgaardia hudsonensis and Chitinophaga rupis has higher NMN production activity than previously known NAMPT from Haemophilus ducreyi and Shewanella oneidensis, thereby completing the present invention.

[0024] The present invention relates to the following 1 to 8.

[0025] 1. A protein according to any one of the following [1] to [3], which has nicotinamide phosphoribosyltransferase activity.

[0026] [1] A protein consisting of the amino acid sequence shown in SEQ ID NO: 3 or 5

[0027] [2] A mutant protein consisting of an amino acid sequence in which 1 to 20 amino acids are deleted, substituted, inserted or added to the amino acid sequence shown in SEQ ID NO: 3 or 5

[0028] [3] A homologous protein consisting of an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 3 or 5

[0029] 2. A DNA encoding the protein described in 1 above.

[0030] 3. The DNA according to 2 above, which is the DNA described in any one of the following [4] to [6].

[0031] [4] A DNA consisting of the base sequence shown in SEQ ID NO: 2 or 4

[0032] [5] A DNA that hybridizes under stringent conditions with a DNA consisting of a base sequence complementary to the base sequence represented by SEQ ID NO: 2 or 4

[0033] [6] A DNA consisting of a base sequence having 90% or more identity with the base sequence shown in SEQ ID NO: 2 or 4

[0034] 4. A recombinant DNA comprising the DNA described in 2 or 3 above.

[0035] 5. A transformant obtained by transforming a host cell with the recombinant DNA described in 4 above.

[0036] 6. The transformant according to 5 above, wherein the productivity of nicotinamide mononucleotide (NMN) is enhanced compared to the host cell.

[0037] 7. The transformant according to 5 above, wherein the host cell is Escherichia coli.

[0038] 8. A method for producing nicotinamide mononucleotide (NMN), comprising producing NMN using the transformant according to any one of 5 to 7 above.

[0039] 9. A method for producing nicotinamide mononucleotide (NMN), comprising producing NMN using the protein described in 1 above.

[0040] Effects of the Invention

[0041] According to the present invention, a protein having enhanced nicotinamide phosphoribosyltransferase activity can be provided, and a method for efficiently producing nicotinamide mononucleotide using the protein can be provided. DETAILED DESCRIPTION

[0042] 1. Protein of the present invention

[0043] The protein of the present invention is a protein described in any one of the following [1] to [3] having nicotinamide phosphoribosyltransferase activity.

[0044] [1] A protein consisting of the amino acid sequence shown in SEQ ID NO: 3 or 5

[0045] [2] A mutant protein consisting of an amino acid sequence in which 1 to 20 amino acids are deleted, substituted, inserted or added to the amino acid sequence shown in SEQ ID NO: 3 or 5

[0046] [3] A homologous protein consisting of an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 3 or 5

[0047] Here, the protein consisting of the amino acid sequence shown in SEQ ID NO: 3 is a protein having nicotinamide phosphoribosyltransferase activity derived from Bisgaardia hudsonensis, and the protein consisting of the amino acid sequence shown in SEQ ID NO: 5 is a protein having nicotinamide phosphoribosyltransferase activity derived from Chitinophaga rupis.

[0048] Nicotinamide phosphoribosyltransferase (NAMPT) condenses nicotinamide (NAM) with 5-phospho-α-D-ribose 1-diphosphate (PRPP) to generate β-nicotinamide mononucleotide (compound name: [(2R,3S,4R,5R)-5-(3-carbamoylpyridine-1- -1-yl)-3,4-dihydroxyoxacyclopentane-2-yl] methyl phosphate; β-NMN) enzyme.

[0049] Nicotinamide phosphoribosyltransferase (NAMPT) activity refers to the activity of synthesizing β-NMN from NAM and PRPP or the activity of synthesizing β-NMN using NAM, PRPP, ATP and water molecules as substrates.

[0050] A mutant protein is a protein obtained by artificially deleting or replacing amino acid residues in a base protein, or artificially inserting or adding amino acid residues into the protein. In the mutant protein of [2], the deletion, replacement, insertion or addition of amino acids may be deletion, replacement, insertion or addition of 1 to 20 amino acids at any position in the amino acid sequence shown in SEQ ID NO: 3 or 5, for example, 1 to 15, 1 to 10, 1 to 5, 1 to 4, 1 to 3, 1 to 2 or 1 amino acid may be deleted, replaced, inserted or added.

[0051] The amino acid to be replaced, inserted or added may be either natural or non-natural. As natural amino acids, L-alanine, L-asparagine, L-aspartic acid, L-glutamine, L-glutamic acid, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-arginine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, L-valine, L-cysteine ​​etc. can be listed.

[0052] Examples of amino acids that can be substituted for each other are shown below. Amino acids included in the same group can be substituted for each other.

[0053] Group A: leucine, isoleucine, norleucine, valine, norvaline, alanine, 2-aminobutyric acid, methionine, o-methylserine, tert-butylglycine, tert-butylalanine, cyclohexylalanine

[0054] Group B: Aspartic acid, Glutamic acid, Isoaspartic acid, Isoglutamic acid, 2-aminoadipic acid, 2-aminosuberic acid

[0055] Group C: Asparagine, Glutamine

[0056] Group D: lysine, arginine, ornithine, 2,4-diaminobutyric acid, 2,3-diaminopropionic acid

[0057] Group E: Proline, 3-hydroxyproline, 4-hydroxyproline

[0058] Group F: serine, threonine, homoserine

[0059] Group G: Phenylalanine, Tyrosine

[0060] Homologous proteins refer to proteins possessed by organisms existing in nature, and are a group of proteins that are derived from the same protein in evolutionary origin. Homologous proteins are similar in structure and function. It is ideal that the amino acid sequence of the homologous protein [3] has an identity of 90% or more, preferably 91% or more, 92% or more, 93% or more, 94% or more, or 95% or more, more preferably 96% or more, 97% or more, or 98% or more, and even more preferably 99% or more, relative to the amino acid sequence shown in SEQ ID NO: 3 or 5.

[0061] The identity of amino acid sequences and base sequences can be determined using the algorithms BLAST [Pro. Nat. Acad. Sci. USA, 90, 5873 (1993)] and FASTA [Methods Enzymol., 183, 63 (1990)] of Karlin and Altschul. Based on the algorithm BLAST, programs called BLASTN and BLASTX were developed [J. Mol. Biol., 215, 403 (1990)]. When BLASTN is used to analyze base sequences based on BLAST, the parameters are set to, for example, Score=100 and wordlength=12. In addition, when BLASTX is used to analyze amino acid sequences based on BLAST, the parameters are set to, for example, score=50 and wordlength=3. When using BLAST and Gapped BLAST programs, the default parameters of each program are used. The specific methods of these analysis methods are well known.

[0062] The fact that the mutant protein of [2] or the homologous protein of [3] has NAPRT activity can be confirmed, for example, by the following method. First, a recombinant DNA having a DNA encoding a protein for which the above activity is to be confirmed is prepared by the method described below. Then, the recombinant DNA is used to transform a microorganism that does not have NAMRT activity or β-NMN production activity, such as Escherichia coli W3110 strain lacking DNA encoding nicotinamidase (pncA gene), DNA encoding nicotinamide mononucleotide amidase (pncC gene), DNA encoding acid phosphatase (aphA gene), DNA encoding 5'-nucleotidase / UDP-hydrolase (ushA gene) and DNA encoding nicotinamide riboside phosphorylase (deoD gene), and the obtained microorganism is cultured, and nicotinamide is added to the culture medium to produce β-NMN. Finally, β-NMN in the culture supernatant is detected using HPLC described below. NAMPT activity can be confirmed by detecting β-NMN.

[0063] 2. DNA of the present invention

[0064] The DNA of the present invention is a DNA encoding the protein of the present invention, that is, the protein of [1], the mutant protein of [2], or the homologous protein of [3] described above.

[0065] Specific examples of the DNA of the present invention include the DNA described in any one of the following [4] to [6].

[0066] [4] A DNA consisting of the base sequence shown in SEQ ID NO: 2 or 4

[0067] [5] A DNA that hybridizes under stringent conditions with a DNA consisting of a base sequence complementary to the base sequence represented by SEQ ID NO: 2 or 4

[0068] [6] A DNA consisting of a base sequence having 90% or more identity with the base sequence shown in SEQ ID NO: 2 or 4

[0069] Here, the DNA shown in sequence number 2 is a DNA obtained by codon-optimizing the base sequence (sequence number 1) of the gene encoding the nicotinamide phosphoribosyltransferase from Bisgaardia hudsonensis shown in sequence number 3 for expression in Escherichia coli, and the DNA shown in sequence number 4 is a gene encoding the nicotinamide phosphoribosyltransferase from Chitinophaga rupis shown in sequence number 5.

[0070] An example of a DNA encoding a protein consisting of the amino acid sequence shown in SEQ ID NO: 3 is a DNA having a base sequence shown in SEQ ID NO: 2 or SEQ ID NO: 1, and an example of a DNA encoding a protein consisting of the amino acid sequence shown in SEQ ID NO: 5 is a DNA having a base sequence shown in SEQ ID NO: 4. An example of a DNA encoding a mutant protein of the above-mentioned 1 [2] or a homologous protein of [3] is, for example, a DNA of the above-mentioned [4] or [5].

[0071] Regarding the DNA in [5], hybridization refers to the step of hybridizing DNA with a DNA having a specific base sequence or a portion of the DNA. Therefore, the base sequence of the DNA hybridizing with the DNA having a specific base sequence or a portion thereof may be a DNA of a length useful as a probe for Northern or Southern blot analysis or as an oligonucleotide primer for PCR analysis.

[0072] Examples of DNA used as a probe include DNA having at least 100 bases, preferably 200 bases or more, and more preferably 500 bases or more. Examples of DNA used as a primer include DNA having at least 10 bases, preferably 15 bases or more.

[0073] The method of DNA hybridization experiment is well known. For example, the hybridization conditions can be determined and the experiment can be performed according to various other standard textbooks such as Molecular Cloning 4th Edition (Cold Spring Harbor Laboratory Press (2012)), Methods for General and Molecular Bacteriology (ASM Press (1994)), and Immunology methods manual (Academic press (1997)).

[0074] In addition, DNA hybridized under stringent conditions can also be obtained according to the instructions attached to commercially available hybridization kits. Commercially available hybridization kits include, for example, a random primer DNA labeling kit (manufactured by Roche Diagnostics) that prepares probes by the random primer method and hybridizes under stringent conditions.

[0075] The above-mentioned stringent conditions refer, for example, to the following conditions: after incubating the filter membrane fixed with DNA and the probe DNA in a solution containing 50% formamide, 5×SSC (750 mM sodium chloride, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5×Denhart's solution, 10% dextran sulfate and 20 μg / L denatured salmon sperm DNA at 42°C for one night, the filter membrane is washed in a 0.2×SSC solution at about 65°C.

[0076] The above-mentioned various conditions can also be set by adding or changing the blocking reagent used to suppress the background of the hybridization experiment. In order to match the conditions, the addition of the above-mentioned blocking reagent can be accompanied by the change of the hybridization conditions.

[0077] Examples of DNAs capable of hybridizing under the above-mentioned stringent conditions include DNAs consisting of base sequences having an identity of 90% or more, preferably 91% or more, 92% or more, 93% or more, 94% or more, or 95% or more, more preferably 96% or more, 97% or more, or 98% or more, and further preferably 99% or more to the base sequence represented by SEQ ID NO: 2 or 4, when calculated based on the above-mentioned parameters using programs such as BLAST and FASTA.

[0078] The DNA of the present invention can be obtained, for example, by the following method: Southern hybridization of a chromosomal DNA library of a microorganism, preferably of the genus Bisgaardia or Chitinophaga, more preferably of the genus Bisgaardia or Chitinophaga rupis, using a probe that can be designed based on the base sequence of a DNA encoding a protein consisting of the amino acid sequence shown in SEQ ID NO: 3 or 5; or, PCR [PCR Protocols, Academic Press (1990)] using the above-mentioned chromosomal DNA library as a template using a primer DNA that can be designed based on a DNA encoding a protein consisting of the amino acid sequence shown in SEQ ID NO: 3 or 5.

[0079] The DNA of the present invention can also be obtained, for example, as follows: using a DNA encoding a protein consisting of an amino acid sequence shown in sequence number 3 or 5 (e.g., a DNA consisting of a base sequence shown in sequence number 2 or 4), a mutation is introduced into a base sequence encoding a portion of 1 to 20 amino acid residues located on the DNA, for example, by a site-directed mutagenesis method described in Molecular Cloning, 4th edition (Cold Spring Harbor Laboratory Press (2012)) and Current Protocols in Molecular Biology (JOHN WILEY & SONS, INC.), and replaced with a base sequence encoding other amino acid residues, thereby obtaining. Alternatively, the DNA of the present invention can also be obtained by using a PrimeSTAR Mutagenesis Basal Kit (manufactured by Takara Bio Co., Ltd.) and the like.

[0080] For example, a DNA encoding a mutant protein described in 1 [2] above, which is composed of an amino acid sequence in which 1 to 20 amino acids are deleted, substituted, inserted and / or added in the amino acid sequence shown in sequence number 3 or 5, can be obtained, for example, by using a DNA composed of a base sequence shown in sequence number 2 or 4 as a template and subjecting it to error-prone PCR, etc.

[0081] Alternatively, a DNA encoding a mutant protein of 1 [2] above, which is composed of an amino acid sequence in which 1 to 20 amino acids are deleted, substituted, inserted or added in the amino acid sequence shown in SEQ ID NO: 3 or 5, can be obtained by utilizing a site-directed mutagenesis method using PCR using a set of PCR primers having a base sequence designed at each 5' end so as to introduce the target mutation (deletion, substitution, insertion or addition) [Gene, 77, 51 (1989)].

[0082] In addition, the DNA of the present invention can also be obtained according to the instructions attached to a commercially available site-directed mutagenesis kit. As a commercially available site-directed mutagenesis kit, for example, PrimeSTAR (registered trademark) mutagenesis basic kit (manufactured by Takara Bio) can be cited, which can introduce a mutation (deletion, substitution, insertion or addition) into the position where the target mutation is to be introduced.

[0083] That is, first, a plasmid containing a base sequence designed in a manner that can introduce a target mutation (deletion, substitution, insertion or addition) is used as a template, and a pair of primers for mutation introduction with 15 bases overlapping on the 5' side are designed. At this time, the overlapping portion contains the target mutation. Then, using the primer for mutation introduction, PCR is performed using a plasmid having a base sequence into which the target mutation is to be introduced as a template. When the amplified fragment thus obtained is transformed into Escherichia coli, a plasmid having a base sequence into which the target mutation is introduced can be obtained.

[0084] The DNA encoding the homologous protein described in 1 [3] above, which is composed of an amino acid sequence having 90% or more identity with the amino acid sequence shown in sequence number 3 or 5, can be obtained, for example, by the following method. Specifically, for example, a base sequence having 90% or more identity, preferably 91% or more, 92% or more, 93% or more, 94% or more or 95% or more, more preferably 96% or more, 97% or more or 98% or more, and further preferably 99% or more identity with the base sequence shown in sequence number 2 or 4 is searched in various gene sequence databases, and a probe DNA or primer DNA designed based on the base sequence or amino acid sequence obtained by the search and a microorganism having the DNA can be used to obtain the DNA encoding the homologous protein by the same method as the above-mentioned method for obtaining the DNA encoding the protein composed of the amino acid sequence shown in sequence number 3 or 5.

[0085] The identity of the base sequence and amino acid sequence can be determined by the same method as in 1 above. In addition, whether the mutant protein or homologous protein encoded by the DNA of the present invention has NAPRT activity can be confirmed by the same method as in 1 above.

[0086] The DNA of the present invention obtained by the above method is directly or cut with an appropriate restriction enzyme and then integrated into a vector by a conventional method. The obtained recombinant DNA is introduced into a host cell and then analyzed using a commonly used base sequence analysis method, such as the dideoxy method [Proc. Nat. Acad. Sci., USA, 74, 5463 (1977)] or a base sequence analysis apparatus such as Applied Biosystems 3500 Gene Analyzer, Applied Biosystems 3730 DNA Analyzer (both manufactured by Thermo Fisher Scientific Inc.), thereby determining the base sequence of the DNA.

[0087] Examples of vectors that can be used when determining the base sequence of the DNA of the present invention include pBluescriptII KS(+), pPCR-Script Amp SK(+) (all manufactured by Agilent Technologies, Inc.), pT7Blue (manufactured by Merck Millipore Corporation), pCRII (manufactured by Thermo Fisher Scientific), pCR-TRAP (manufactured by Din Handa Corporation), and pDIRECT [Nucleic Acids Res., 18, 6069 (1990)].

[0088] The host cell may be any cell into which the vector is introduced and which can be grown, and examples thereof include Escherichia coli DH5α, Escherichia coli HST08 Premium, Escherichia coli HST02, Escherichia coli HST04 dam- / dcm-, Escherichia coli JM109, Escherichia coli HB101, Escherichia coli CJ236, Escherichia coli BMH71-18 mutS, Escherichia coli MV1184, Escherichia coli TH2 (all manufactured by Takara Bio), Escherichia coli XL1-Blue, Escherichia coli XL2-Blue (all manufactured by Agilent Technologies), Escherichia coli DH1, Escherichia coli MC1000, Escherichia coli W1485, Escherichia coli W3110, Escherichia coli MP347, and Escherichia coli NM522.

[0089] As a method for introducing the recombinant DNA obtained by integrating the DNA of the present invention into a host cell, any method for introducing DNA into a host cell can be used, and examples thereof include a method using calcium ions [Proc. Natl. Acad. Sci., USA, 69, 2110 (1972)], a protoplast method (Japanese Patent Application Laid-Open No. 63-248394), and an electroporation method [Nucleic Acids Res., 16, 6127 (1988)].

[0090] When the DNA obtained as a result of base sequence determination is partial length, the full length DNA can be obtained by Southern hybridization or the like with a chromosomal DNA library using the partial length DNA as a probe.

[0091] Furthermore, the target DNA can also be prepared by chemical synthesis based on the determined DNA base sequence using an NTSM series DNA synthesizer manufactured by Japan Technosapiens Co., Ltd. or the like.

[0092] 3. Recombinant DNA of the present invention

[0093] The recombinant DNA of the present invention contains the DNA of the present invention. The recombinant DNA of the present invention is a DNA capable of autonomous replication in a host cell, and is a DNA in which the DNA of the present invention is integrated into an expression vector containing a promoter at a position capable of transcribing the DNA of the present invention described in 2 above.

[0094] In addition, a DNA having the DNA of the present invention which can be integrated into a chromosome in a host cell is also the recombinant DNA of the present invention.

[0095] When the recombinant DNA is a recombinant DNA that can be integrated into a chromosome, it may or may not contain a promoter.

[0096] When prokaryotes such as bacteria are used as host cells, the recombinant DNA of the present invention is preferably a recombinant DNA consisting of a promoter, a ribosome binding sequence, the DNA of the present invention described in 2 above, and a transcription termination sequence. Furthermore, a gene that controls the promoter may be contained.

[0097] Here, it is preferred that the distance between the Shine-Dalgarno sequence, which is a ribosome binding sequence, and the start codon be adjusted to an appropriate distance, for example, 6 to 18 bases.

[0098] In the recombinant DNA of the present invention, a transcription termination sequence is not necessarily required for the expression of the DNA of the present invention, but it is preferably arranged immediately downstream of the structural gene.

[0099] The expression vector is not particularly limited as long as it is an appropriate nucleic acid molecule that can introduce the target DNA into a host, propagate, and express it. Not only plasmids but also artificial chromosomes, vectors using transposons, and cosmids can be used.

[0100] When a microorganism belonging to the genus Escherichia is used as a host cell for introducing the recombinant DNA of the present invention, examples of expression vectors include pColdI, pSTV28, pSTV29, pUC118 (all manufactured by Takara Bio), pET21a, pCDF-1b, pRSF-1b (all manufactured by Merck Millipore), pMAL-c5x (Nuclear Grain Biolabs), pGEX-4T-1, pTrc99A (all manufactured by GE Healthcare Biosciences), pTrcHis, pSE280 (all manufactured by Thermo Fisher Scientific), pGEMEX-1 (manufactured by Promega), pQE-30, pQE-60, pQE80L (all manufactured by Keagen), pET-3, pBluescriptII SK(+), pBluescriptII KS(-) (all manufactured by Agilent Technologies), pKYP10 (Japanese Patent Application Laid-Open No. 58-110600), pKYP200 [Agric.Biol.Chem., 48, 669 (1984)], pLSA1 [Agric.Biol.Chem., 53, 277 (1989)], pGEL1 [Proc.Natl.Acad.Sci., USA, 82, 4306 (1985)], pTrS30 [prepared from Escherichia coli JM109 / pTrS30 (FERM BP-5407)], pTrS32 [prepared from Escherichia coli JM109 / pTrS32 (FERM BP-5408)], pTK31 [APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2007, Vol. 73, No. 20, p6378-6385], pPE167 (Appl. Environ. Microbiol. 2007, 73: 6378-6385), pPAC31 (WO98 / 12343), pUC19 [Gene, 33, 103 (1985)], pPA1 (Japanese Patent Application Publication No. 63-233798), etc.

[0101] The promoter used in the expression vector may be any promoter that functions in cells of microorganisms belonging to the genus Escherichia, for example, trp promoter, gapA promoter, lac promoter, PL promoter, PR promoter, PSE promoter, etc., which are derived from Escherichia coli, bacteriophage, etc. In addition, artificially designed and modified promoters such as a promoter in which two trp promoters are linked in series, a tac promoter, a trc promoter, a lacT5 promoter, a lacT7 promoter, and a letI promoter may also be used.

[0102] When coryneform bacteria are used as host cells for introducing the recombinant DNA of the present invention, examples of expression vectors include pCG1 (Japanese Patent Application Laid-Open No. 57-134500), pCG2 (Japanese Patent Application Laid-Open No. 58-35197), pCG4 (Japanese Patent Application Laid-Open No. 57-183799), pCG11 (Japanese Patent Application Laid-Open No. 57-134500), pCG116, pCE54, pCB101 (all see Japanese Patent Application Laid-Open No. 58-105999), pCE51, pCE52, pCE53 [all see Molecular and General Genetics, 196, 175 (1984)] and the like.

[0103] When the expression vector is used, any promoter that functions in cells of coryneform bacteria may be used as the promoter. For example, the P54-6 promoter [Appl. Microbiol. Biotechnol., 53, p674-679 (2000)] may be used.

[0104] When a yeast strain is used as a host cell for introducing the recombinant DNA of the present invention, examples of expression vectors include YEp13 (ATCC37115), YEp24 (ATCC37051), YCp50 (ATCC37419), pHS19, and pHS15.

[0105] The promoter used in the expression vector may be any promoter that functions in cells of yeast strains, and examples thereof include PHO5 promoter, PGK promoter, GAP promoter, ADH promoter, gal1 promoter, gal10 promoter, heat shock polypeptide promoter, MFα1 promoter, and CUP1 promoter.

[0106] The recombinant DNA of the present invention can be produced, for example, by subjecting the DNA fragment prepared by the method 2 above to restriction enzyme treatment or the like and then inserting the fragment into the downstream of the promoter of the above-mentioned appropriate expression vector.

[0107] Here, the expression level of the protein encoded by the DNA can also be increased by replacing the base sequence of the DNA of the present invention with the codons most suitable for expression in the host cell. Information on the codon usage frequency in the host cell can be obtained from public databases.

[0108] 4. Transformants of the present invention

[0109] The transformant of the present invention is a transformant obtained by transforming a host cell with the recombinant DNA described in 3 above containing the DNA of the present invention described in 2 above. The transformant of the present invention is preferably a transformant having enhanced productivity of nicotinamide mononucleotide (NMN) compared to the host cell.

[0110] The host cell into which the recombinant DNA of the present invention is introduced may be any of prokaryotes, yeasts, animal cells, insect cells, plant cells, and the like. Preferred examples include prokaryotes or yeast strains, and more preferred examples include prokaryotes belonging to the genera Escherichia, Serratia, Bacillus, Brevibacterium, Corynebacterium, Microbacterium, or Pseudomonas, or yeast strains belonging to the genera Saccharomyces, Schizosaccharomyces, Kluyveromyces, Trichosporon, Schwannoma, Pichia, or Candida. Particularly preferred examples include Escherichia coli.

[0111] Specific examples of preferred host cells include Escherichia coli BL21 codon plus, Escherichia coli XL1-Blue, Escherichia coli XL2-Blue (all manufactured by Agilent Technologies), Escherichia coli BL21 (DE3) pLysS (manufactured by Merck Millipore), Escherichia coli DH5α, Escherichia coli HST08 Premium, Escherichia coli HST02, Escherichia coli HST04 dam- / dcm-, Escherichia coli JM109, Escherichia coli HB101, Escherichia coli CJ236, and Escherichia coli BMH71-18. mutS, Escherichia coli MV1184, Escherichia coli TH2 (all manufactured by Takara Bio), Escherichia coli W, Escherichia coli JM101, Escherichia coli W3110, Escherichia coli MG1655, Escherichia coli DH1, Escherichia coli MC1000, Escherichia coli W1485, Escherichia coli MP347, Escherichia coli NM522, Escherichia coli ATCC9637, Serratia ficaria, Serratia fonticola, Serratia liquefaciens, Serratia marcescens, Bacillus subtilis, Bacillus amyloliquefaciens, Brevibacterium immariophilum ATCC14068, Brevibacterium saccharolyticum saccharolyticum ATCC14066, Corynebacterium ammoniagenes, Corynebacterium glutamicum ATCC13032, Corynebacterium glutamicum ATCC14067, Corynebacterium glutamicum ATCC13869, Corynebacterium acetoacidophilum ATCC13870, Microbacterium ammoniaphilum ATCC15354 or Pseudomonas sp.)D-0110 or other prokaryotes or yeast strains such as Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces lactis, Trichosporon pullulans, Schwanniomyces alluvius, Pichia pastoris or Candida utilis.

[0112] As host cells, preferably used are strains in which the activity to degrade nicotinamide or β-nicotinamide mononucleotide is artificially weakened, strains in which the productivity of nicotinamide, which is a substrate of the target β-nicotinamide mononucleotide, is artificially imparted or enhanced, or strains in which both are achieved.

[0113] Examples of methods for artificially weakening the nicotinamide or β-nicotinamide mononucleotide-degrading activity of cells used as host cells, particularly microorganisms, include methods of weakening or cutting at least one enzyme having nicotinamide or β-nicotinamide mononucleotide-degrading activity.

[0114] Examples of methods for artificially imparting or enhancing the ability (productivity) to produce nicotinamide to cells, particularly microorganisms, used as host cells include: (a) a method of relaxing or canceling at least one mechanism controlling the biosynthetic pathway for producing the target nicotinamide, (b) a method of enhancing the expression of at least one enzyme involved in the biosynthetic pathway for producing the target nicotinamide, (c) a method of increasing the copy number of at least one enzyme gene involved in the biosynthetic pathway for producing the target nicotinamide, and (d) a method of weakening or disconnecting at least one metabolic pathway that branches from the biosynthetic pathway for producing the target nicotinamide to a metabolite other than the target substance. The above-known methods can be used alone or in combination.

[0115] Specific examples of the above-mentioned method of weakening the decomposition activity of nicotinamide or β-nicotinamide mononucleotide and imparting or enhancing the productivity of nicotinamide as a substrate include known methods such as methods based on various gene manipulations (International Publication No. 2018 / 211028).

[0116] Specifically, for example, in order to further improve the productivity of NMN using Escherichia coli as a host cell as described in Non-Patent Document 5, enhancement of NiaP as a nicotinamide uptake system, enhancement of PnuC as an NMN excretion system, enhancement of PrsA as a PRPP synthase, etc. can be performed.

[0117] In addition, as disclosed by William B. Black et al. (Microbial Cell Factories 19 (2020) 150), it is possible to destroy pncC, which is a part of the NMN decomposition system, enhance NRK1, which is a part of the NMN synthesis system, and destroy NAD repressor nadR, the main purpose of which is to shut down the NMN decomposition system.

[0118] Grose et al. (Journal of Bacteriology 187 (2005) 4521-4530) reported aphA as an NMN decomposition system and pncA as a decomposition system for substrate nicotinamide in Salmonella, and predicted that the productivity of NMN could be increased by destroying these enzymes that also exist in Escherichia coli.

[0119] Furthermore, Chakwan Siew et al. (Journal of Biological Chemistry 286 (2011) 40365-40375) reported pncC as an NMN decomposition system, and Yang Liu et al. (Microbial Biotechnology 14 (2021) 2581-2591) mentioned the destruction of purR as a regulator of purine nucleic acid and the destruction of AMP degrading enzyme amn in order to increase PRPP supply. Patent document 3 discloses that in addition to the above-mentioned breeding, ushA, deoD, rihA, rihB, and rihC are destroyed to inhibit various decompositions, so it is predicted that the destruction of these enzymes can also lead to an increase in NMN productivity.

[0120] Examples of methods for introducing the recombinant DNA of any one of the above 3 into a plasmid capable of autonomously replicating in a host cell include the above-mentioned method using calcium ions, the protoplast method, the electroporation method, the spheroplast method [Proc. Natl. Acad. Sci., USA, 81, 4889 (1984)], and the lithium acetate method [J. Bacteriol., 153, 163 (1983)].

[0121] As a method for integrating recombinant DNA into the chromosome of a host cell, for example, homologous recombination can be cited. As a homologous recombination method, for example, a method using a homologous recombination plasmid can be cited, and the homologous recombination plasmid can be prepared by connecting with a plasmid DNA having a drug resistance gene that cannot replicate autonomously in the host cell to be introduced. As a method using homologous recombination frequently used in Escherichia coli, for example, a method for introducing recombinant DNA using the homologous recombination system of λ phage can be cited [Proc. Natl. Acad. Sci. USA, 97, 6641-6645 (2000)].

[0122] Furthermore, by using a selection method that utilizes the fact that Escherichia coli is made sucrose sensitive by integrating Bacillus subtilis levansucrase into the chromosome together with the recombinant DNA, or a selection method that utilizes the fact that Escherichia coli is made streptomycin sensitive by integrating the wild-type rpsL gene into Escherichia coli with a mutant rpsL gene having streptomycin resistance [Mol.Microbiol., 55, 137 (2005), Biosci.Biotechnol.Biochem., 71, 2905 (2007)], it is possible to obtain Escherichia coli in which the target region on the chromosomal DNA of the host cell is replaced with the recombinant DNA.

[0123] The fact that the transformant obtained by the above method has the DNA of the present invention described in 2 above can be confirmed, for example, by culturing the transformant in a culture medium and comparing the amount of target NMN accumulated in the culture with that of the parent strain (host cell). Alternatively, an extract containing the protein of the present invention is prepared from the culture, and the extract and two different nicotinamides are allowed to exist in an aqueous medium, and the amount of NMN accumulated in the aqueous medium is compared with that of the parent strain, thereby confirming it.

[0124] Examples of such transformants of the present invention include the transformants described in the Examples described below.

[0125] 5. Method for producing nicotinamide mononucleotide of the present invention

[0126] As a method for producing nicotinamide mononucleotide (NMN) of the present invention, a method for producing NMN based on a fermentation method can be cited, which is characterized in that a microorganism having the ability to produce the protein of the present invention described in 1 above is cultured in a culture medium, and NMN is produced in the culture. The production method may include, for example, the following steps: after NMN is produced in the culture, it is accumulated and NMN is collected from the culture.

[0127] As a microorganism used in the method for producing NMN by a fermentation method, it is preferred to use the transformant of the present invention described in 4 above. In addition, it is preferred to use a transformant having the ability to produce nicotinamide, which is a substrate of NMN, and / or a transformant in which the decomposition activity of nicotinamide or NMN is artificially weakened.

[0128] The method for culturing the transformant of 4 above can be carried out according to a conventional method used for culturing microorganisms.

[0129] The medium for culturing the transformant may be any medium as long as it contains a carbon source, a nitrogen source, an inorganic salt, etc. that the transformant can assimilate and can efficiently culture the transformant. Either a natural medium or a synthetic medium can be used.

[0130] Any substance that can be assimilated by the transformant may be used, for example, sugars such as glucose, fructose, sucrose, molasses containing these, starch or starch hydrolyzate, organic acids such as acetic acid and propionic acid, or alcohols such as glycerol, ethanol or propanol.

[0131] As nitrogen sources, for example, ammonium salts of inorganic or organic acids such as ammonia, ammonium chloride, ammonium sulfate, ammonium acetate or ammonium phosphate, other nitrogen-containing compounds, as well as peptone, meat extract, yeast extract, corn steep liquor, casein hydrolyzate, soybean meal, soybean meal hydrolyzate, various fermented bacteria and their digests can be used.

[0132] Examples of the inorganic salt include potassium dihydrogen phosphate, dipotassium hydrogen phosphate, magnesium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, copper sulfate, and calcium carbonate.

[0133] In the method for producing NMN by a fermentation method, when the transformant used does not have the ability to produce nicotinamide as a substrate, nicotinamide is added to the medium during the culture.

[0134] In addition, in the method for producing NMN based on the fermentation method, when the transformant used does not have the ability to produce nicotinamide as a substrate, nicotinamide can be supplied to the transformant of the present invention by culturing a microorganism having the ability to produce nicotinamide together with the transformant of the present invention instead of adding nicotinamide to the culture medium during the culture.

[0135] Cultivation is usually preferably carried out under aerobic conditions such as shaking culture or deep aeration stirring culture. The culture temperature is usually 15 to 40°C, and the culture time is usually 5 hours to 7 days. The pH of the culture solution during cultivation is usually maintained at 3.0 to 9.0. The pH is adjusted by using inorganic or organic acids, alkaline solutions, urea, calcium carbonate, ammonia, etc.

[0136] In addition, antibiotics such as ampicillin and tetracycline can be added to the culture medium as needed during the culture. When a microorganism transformed by an expression vector using an inducible promoter as a promoter is cultured, an inducer can be added to the culture medium as needed. For example, when a microorganism transformed by an expression vector using a lac promoter is cultured, isopropyl-β-D-thiogalactopyranoside (IPTG) and the like can be added to the culture medium, and when a microorganism transformed by an expression vector using a trp promoter is cultured, indole acrylic acid and the like can be added to the culture medium.

[0137] By the above-mentioned culture, NMN is produced in the culture, thereby NMN can be produced. Specifically, for example, NMN can be produced by producing and accumulating NMN in the culture and collecting NMN from the culture.

[0138] The obtained NMN can be analyzed by conventional methods such as high performance liquid chromatography (HPLC). Collection of NMN from the above-mentioned culture or the processed product of the culture can be performed by conventional methods such as activated carbon, ion exchange resin, etc. When NMN accumulates in the bacteria, for example, the bacteria can be disrupted by ultrasound, the bacteria can be removed by centrifugation, and NMN can be collected from the obtained supernatant using activated carbon, ion exchange resin, etc.

[0139] The method for producing NMN of the present invention may also be a method for producing NMN using the protein of the present invention. NMN can be produced by reacting the protein of the present invention with nicotinamide as its substrate.

[0140] Examples of the present invention are described below, but the present invention is not limited to these examples.

[0141] Example

[0142] [Analysis example] Analysis and quantification of NMN

[0143] In the Examples, analysis and quantification of NMN were performed using an analyzer SPD-20AV (manufactured by Shimadzu Corporation).

[0144] (Analysis conditions)

[0145] Column: Shodex Asahipak MN2P-50 4E 4.6Φ, 250mm, 5μm (manufactured by Showa Denko K.K.)

[0146] Column temperature: 30°C

[0147] Mobile phase: 50 mM ammonium formate (pH 4.0): acetonitrile = 60:40 (v / v)

[0148] Flow rate: 0.6ml / min

[0149] Detection wavelength: 260nm

[0150] [Example 1] Preparation of microorganisms expressing various NAMPTs

[0151] (1) Acquisition of DNA encoding NAMPT

[0152] PCR was performed using the DNA described in "Template" in Table 1 as a template and the "primer set" described in Table 1 to amplify the target DNA fragment.

[0153]

[0154] The DNA shown in sequence number 2 is a DNA prepared by artificial synthesis in which the base sequence (sequence number 1) encoding the nicotinamide phosphoribosyltransferase nadV (hereinafter referred to as "BhnadV") from Bisgaardia hudsonensis shown in sequence number 3 is codon-optimized for expression in Escherichia coli. The chromosomal DNA of Chitinophaga rupis is prepared according to conventional methods. CrnadV (sequence number 4) is a gene encoding nadV (sequence number 5) (hereinafter referred to as "CrnadV") from Chitinophaga rupis. It should be noted that the GenBank accession number of the genomic DNA of the M327 / 99 / 2 strain of Bisgaardia hudsonensis is CP016605.1, and the GenBank accession number of the genomic DNA of the DSM 21039 strain of Chitinophaga rupis is NZ_FOBB01000001.1.

[0155] PCR was performed using the expression vector pTrc99A (E Amann, B Ochs, KJ Abel 1988 Gene 30; 69(2): 301-315) as a template and a DNA fragment consisting of the base sequence shown in sequence numbers 17 and 18 as a primer set to obtain a vector fragment of about 4.0 kb.

[0156] Forward primer: 5'-tgcctggcggcagtagcg-3' (SEQ ID NO: 17)

[0157] Reverse primer: 5'-ggtctgtttcctgtgtgaaat-3' (SEQ ID NO: 18)

[0158] It should be noted that the base sequences shown in SEQ ID NOs: 13, 15 and 18 and SEQ ID NOs: 14, 16 and 17 contain complementary sequences at their respective 3' ends.

[0159] The obtained amplified DNA fragment containing BhnadV or CrnadV and the vector fragment were ligated using In-Fusion HD Cloning Kit (manufactured by Takara Bio Co., Ltd.) to prepare plasmids, pBhnadV and pCrnadV, for expressing various NAMPTs.

[0160] (2) Preparation of co-expression plasmid

[0161] The following method was used to prepare a plasmid for NAMPT expression in which the genes encoding various NAMPTs obtained in (1) above and the gene encoding ribose-phosphate diphosphokinase (PrsA) from Escherichia coli shown in SEQ ID NO: 12 were arranged under the trc promoter. It should be noted that the GenBank accession number of the genomic DNA of the Escherichia coli BL21 strain is CP053602.1.

[0162] Using the expression vector pTrc99A as a template, PCR was performed using a DNA consisting of the base sequence shown in sequence numbers 19 and 18 as a primer set to obtain a trc promoter fragment of about 250 bp. Using the chromosomal DNA of the Escherichia coli BL21 strain prepared according to a conventional method as a template, PCR was performed using a DNA consisting of the base sequence shown in sequence numbers 20 and 21 as a primer set to obtain a prsA fragment of about 950 bp.

[0163] Forward primer: 5'-gcgcgaattgatctggtttgacagcttatcatcg-3' (SEQ ID NO: 19)

[0164] Reverse primer: 5'-ggtctgtttcctgtgtgaaat-3' (SEQ ID NO: 18)

[0165] Forward primer: 5'-tttcacacaggaaacagaccatgaagctttttgctggtaacg-3' (SEQ ID NO: 20)

[0166] Reverse primer: 5'-tttcacacaggaaacagaccatgaagctttttgctggtaacg-3' (SEQ ID NO: 21)

[0167] PCR was performed using the trc promoter fragment and prsA fragment obtained above as templates and DNA consisting of the base sequences shown in SEQ ID NOs: 19 and 21 as a primer set to obtain a DNA fragment of about 1200 bp (hereinafter referred to as Ptrc-prsA fragment).

[0168] Using pBhnadV and pCrnadV prepared in (1) above as templates and DNA consisting of the base sequences shown in SEQ ID NOs: 22 and 23 as primer sets, PCR was performed to obtain vector fragments of about 5.5 kb (hereinafter referred to as pBhnadV fragment and pCrnadV fragment), respectively.

[0169] Forward primer: 5'-gtttgacagcttatcatcgac-3' (SEQ ID NO: 22)

[0170] Reverse primer: 5'-cagatcaattcgcgctaactc-3' (SEQ ID NO: 23)

[0171] The Ptrc-prsA fragment obtained above was ligated with the pBhnadV fragment or the pCrnadV fragment using the In-Fusion HD Cloning Kit (manufactured by Takara Bio) to prepare pPrsA-BhnadV and pPrsA-CrnadV, which are plasmids for co-expressing various NAMPTs and PrsA.

[0172] (3) Preparation of Escherichia coli with co-expression plasmid

[0173] The Escherichia coli W3110 strain was transformed with the various co-expression plasmids obtained in (2) above to prepare Escherichia coli strains harboring the various plasmids, which were named W3110 / pPrsA-BhnadV and W3110 / pPrsA-CrnadV, respectively.

[0174] [Comparative Example 1] Preparation of microorganisms expressing known NAMPT

[0175] (1) Acquisition of NAMPT sequences

[0176] PCR was performed using the DNA described in "Template" in Table 2 as a template and the "primer set" described in Table 2 to amplify the target DNA fragment.

[0177]

[0178] The chromosomal DNA of Shewanella oneidensis is prepared according to conventional methods. The DNA shown in sequence number 6 encodes the nicotinamide phosphoribosyltransferase nadV (hereinafter referred to as "SonadV") from Shewanella oneidensis shown in sequence number 7. The DNA shown in sequence number 9 is a DNA in which the base sequence (sequence number 8) of the gene encoding the nicotinamide phosphoribosyltransferase nadV (hereinafter referred to as "HdnadV") from Haemophilus ducreyi shown in sequence number 10 is codon-optimized for expression in Escherichia coli, and is prepared by artificial synthesis. It should be noted that the base sequences shown in sequence numbers 24, 26 and 18, and sequence numbers 25, 27 and 17 contain complementary sequences at their respective 5' ends. It should be noted that the GenBank accession number of the genomic DNA of Shewanella Oneida strain MR-1 is CP053946.1, and the GenBank accession number of the genomic DNA of Haemophilus ducreyi strain FDAARGOS 297 is CP022037.2.

[0179] The obtained amplified DNA fragments containing SonadV or HdnadV were ligated with the vector fragment prepared in Example 1(1) using In-Fusion HD Cloning Kit (Takara Bio Co., Ltd.) to prepare plasmids expressing various NAMPTs, pSonadV and pHdnadV.

[0180] (2) Preparation of co-expression plasmid

[0181] A plasmid for expressing the gene in which a gene encoding various NAMPTs and a gene encoding ribose-bisphosphate kinase (PrsA) derived from Escherichia coli were arranged under the trc promoter was prepared by the following method.

[0182] Using pSonadV and pHdnadV prepared in (1) above as templates and DNA consisting of the base sequences shown in SEQ ID NOs: 22 and 23 as primer sets, PCR was performed to obtain vector fragments of about 5.5 kb (hereinafter referred to as pSonadV fragment and pHdnadV fragment), respectively.

[0183] The Ptrc-prsA fragment obtained in Example 1 (2) was ligated with the pSonadV fragment or pHdnadV fragment using the In-Fusion HD Cloning Kit (manufactured by Takara Bio) to prepare plasmids, pPrsA-SonadV and pPrsA-HdnadV, for co-expressing various NAMPTs and PrsA.

[0184] (3) Preparation of Escherichia coli with co-expression plasmid

[0185] The Escherichia coli W3110 strain was transformed with the co-expression plasmid obtained above to prepare Escherichia coli strains carrying various plasmids, which were named W3110 / pPrsA-SonadV and W3110 / pPrsA-HdnadV, respectively.

[0186] [Example 2] Production of NMN

[0187] The productivity of NMN was evaluated for the W3110 / pPrsA-BhnadV strain and the W3110 / pPrsA-CrnadV strain prepared in Example 1. As positive controls, W3110 / pPrsA-SonadV and W3110 / pPrsA-HdnadV prepared in Comparative Example 1 were used.

[0188] Each strain was inoculated into a 5 mL crude test tube containing LB medium [BACTO tryptone (manufactured by Difuco) 10 g / L, yeast extract (manufactured by Difuco) 5 g / L, sodium chloride 10 g / L] containing 100 mg / L of ampicillin, and cultured with shaking at 30°C for 20 hours. 1% of the obtained culture solution was inoculated into a 5 mL crude test tube containing LB medium containing 100 mg / L of ampicillin, and cultured with shaking at 30°C for 16 hours. IPTG was added 2 hours after the start of culture to a final concentration of 0.5 mM.

[0189] After the culture is completed, each 5 mL of the culture solution is centrifuged, and the supernatant is removed to obtain wet cells. All the wet cells are suspended in a thick test tube containing 5 mL of reaction medium (3 g / L potassium dihydrogen phosphate, 6.8 g / L disodium hydrogen phosphate, 0.5 g / L sodium chloride, 1 g / L ammonium chloride, 20 g / L glucose, 0.25 g / L magnesium sulfate heptahydrate, 14.7 mg / L calcium chloride, and 2.6 g / L NAM), and reacted by shaking at 30 ° C for 2 hours. After the reaction, the reaction solution is centrifuged and the supernatant is provided for the analysis of NMN. The experiment was performed three times independently. The results are shown in Table 3.

[0190]

[0191] The above results show that BhnadV and CrnadV have higher NMN production activity than SonadV and HdnadV, which are known NAMPTs. In particular, BhnadV has a NMN productivity that is more than 10 times higher than that of the known NAMPT, indicating that NMN can be efficiently produced by using this enzyme.

Claims

1. A protein having nicotinamide phosphoribosyltransferase activity, which is the protein described in any one of the following [1] to [3], [1] A protein consisting of the amino acid sequence shown in SEQ ID NO: 3 or 5; [2] A mutant protein having an amino acid sequence in which 1 to 20 amino acids are deleted, substituted, inserted or added to the amino acid sequence of SEQ ID NO: 3 or 5; [3] A homologous protein consisting of an amino acid sequence having an identity of 90% or more to the amino acid sequence shown in SEQ ID NO: 3 or 5.

2. A DNA encoding the protein according to claim 1.

3. The DNA according to claim 2, which is the DNA described in any one of the following [4] to [6], [4] A DNA consisting of the base sequence represented by SEQ ID NO: 2 or 4; [5] A DNA that hybridizes under stringent conditions with a DNA consisting of a base sequence complementary to the base sequence represented by SEQ ID NO: 2 or 4; [6] A DNA consisting of a base sequence having 90% or more identity with the base sequence shown in SEQ ID NO: 2 or 4. A recombinant DNA comprising the DNA according to claim 2 or 3.

5. A transformant obtained by transforming a host cell with the recombinant DNA according to claim 4. The transformant according to claim 5, wherein the productivity of nicotinamide mononucleotide (NMN) is enhanced compared to a host cell.

7. The transformant according to claim 5, wherein The host cell is Escherichia coli.

8. A method for producing nicotinamide mononucleotide (NMN), comprising producing NMN using the transformant according to claim 5.

9. A method for producing nicotinamide mononucleotide (NMN), comprising producing NMN using the protein according to claim 1.

Citation Information

Patent Citations

  • Production of 5'-guanylic acid

    JP1988233798A

  • Production of nucleic acid-relating substance

    JP1988248394A

  • Processes for producing sugar nucleotides and complex carbohydrates

    WO1998012343A1

  • Efficient synthesis of nicotinamide mononucleotide

    WO2016160524A1

  • β-nicotinamide mononucleotide-containing solid yeast extract and method for producing same

    WO2017022768A1